Could a drug for alcoholism tame arthritis inflammation?

NCT ID NCT07534332

Not yet recruiting Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether disulfiram, a drug already approved for alcohol use disorder, can safely reduce joint inflammation in people with rheumatoid arthritis who are overweight. Twenty adults with active arthritis despite standard treatment will take either disulfiram or a placebo daily for 12 weeks. The study focuses on safety and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Disulfiram
What this could lead to: If it works, this could point toward a new way to control inflammation in rheumatoid arthritis, especially for patients who are overweight.
What could go wrong: This is a small, early pilot trial with only 20 people, so results may not apply widely. Disulfiram can cause serious reactions if alcohol is consumed, and its benefit for arthritis is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease Obesity obesity disorder rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION OBESITY RHEUMATOID ARTHRITIS

Contacts and locations

Locations

University of Oklahoma Health Campus

Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.